CareDx (CDNA) Tops Q3 EPS by 36c, Beats on Revenue; Offers FY25 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to CareDx (CDNA) Tops Q3 EPS by 36c, Beats on Revenue; Offers FY25 Revenue Guidance

CareDx Announces Third Quarter 2025 Financial Results

November 4, 2025 4:05 PM EST

Total Revenue of $100 Million Increased 21% Year-Over-Year

Grew Testing Services Volume to Approximately 50,300, Increase of 13% Year-Over-Year

Raised 2025 Revenue Guidance to $372 Million to $376 Million

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2025.

Third Quarter 2025 Financial Highlights

Revenue of $100.1 million, an increase of 21%... More